Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.

Saes JL, Schols SEM, Betbadal KF, van Geffen M, Verbeek-Knobbe K, Gupta S, Hardesty BM, Shapiro AD, van Heerde WL.

Haemophilia. 2019 Nov;25(6):1073-1082. doi: 10.1111/hae.13842. Epub 2019 Aug 30.

PMID:
31469483
2.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

PMID:
31444162
3.

Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia.

Bakeer N, Shapiro AD.

F1000Res. 2019 Jul 9;8. pii: F1000 Faculty Rev-1029. doi: 10.12688/f1000research.16039.1. eCollection 2019. Review.

4.

Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco-Johnson MJ; Joint Outcome Study Group Investigators.

Haemophilia. 2019 Sep;25(5):867-875. doi: 10.1111/hae.13778. Epub 2019 May 21.

PMID:
31115111
5.

Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.

Okolo AI, Soucie JM, Grosse SD, Roberson C, Janson IA, Allen M, Shapiro AD.

Haemophilia. 2019 May;25(3):456-462. doi: 10.1111/hae.13734. Epub 2019 Mar 29.

6.

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.

Shapiro AD, Pasi KJ, Ozelo MC, Kulkarni R, Barnowski C, Winding B, Szamosi J, Lethagen S.

Res Pract Thromb Haemost. 2018 Nov 29;3(1):109-113. doi: 10.1002/rth2.12163. eCollection 2019 Jan.

7.

The future of bypassing agents for hemophilia with inhibitors in the era of novel agents.

Shapiro AD, Mitchell IS, Nasr S.

J Thromb Haemost. 2018 Dec;16(12):2362-2374. doi: 10.1111/jth.14296. Epub 2018 Oct 11. Review.

PMID:
30264916
8.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

9.

Optimizing bleed prevention throughout the lifespan: Womb to Tomb.

Gupta S, Shapiro AD.

Haemophilia. 2018 May;24 Suppl 6:76-86. doi: 10.1111/hae.13471. Review.

PMID:
29878655
10.

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM.

Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.

11.

A null mutation in SERPINE1 protects against biological aging in humans.

Khan SS, Shah SJ, Klyachko E, Baldridge AS, Eren M, Place AT, Aviv A, Puterman E, Lloyd-Jones DM, Heiman M, Miyata T, Gupta S, Shapiro AD, Vaughan DE.

Sci Adv. 2017 Nov 15;3(11):eaao1617. doi: 10.1126/sciadv.aao1617. eCollection 2017 Nov.

12.

A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors.

Shapiro AD.

Haemophilia. 2017 Nov;23(6):810-811. doi: 10.1111/hae.13345. No abstract available.

PMID:
29149550
13.

Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.

Kempton CL, Wang M, Recht M, Neff A, Shapiro AD, Soni A, Kulkarni R, Buckner TW, Batt K, Iyer NN, Cooper DL.

Patient Prefer Adherence. 2017 Sep 19;11:1603-1612. doi: 10.2147/PPA.S141389. eCollection 2017.

14.

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.

15.

Complete Plasminogen Activator Inhibitor 1 Deficiency.

Heiman M, Gupta S, Khan SS, Vaughan DE, Shapiro AD.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2017 Aug 3.

16.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
17.

Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.

Flevaris P, Khan SS, Eren M, Schuldt AJT, Shah SJ, Lee DC, Gupta S, Shapiro AD, Burridge PW, Ghosh AK, Vaughan DE.

Circulation. 2017 Aug 15;136(7):664-679. doi: 10.1161/CIRCULATIONAHA.117.028145. Epub 2017 Jun 6.

18.

Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Doruelo AL, Haberichter SL, Christopherson PA, Boggio LN, Gupta S, Lentz SR, Shapiro AD, Montgomery RR, Flood VH.

J Thromb Haemost. 2017 Aug;15(8):1559-1566. doi: 10.1111/jth.13742. Epub 2017 Jun 23.

19.

Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2017 Jan;18:41-44. doi: 10.1016/j.scr.2016.12.003. Epub 2016 Dec 9.

20.

Generation of human iPSCs from urine derived cells of a non-affected control subject.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2017 Jan;18:33-36. doi: 10.1016/j.scr.2016.12.008. Epub 2016 Dec 9.

21.

Fine-scale foraging movements by fish-eating killer whales (Orcinus orca) relate to the vertical distributions and escape responses of salmonid prey (Oncorhynchus spp.).

Wright BM, Ford JKB, Ellis GM, Deecke VB, Shapiro AD, Battaile BC, Trites AW.

Mov Ecol. 2017 Feb 20;5:3. doi: 10.1186/s40462-017-0094-0. eCollection 2017.

22.

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.

Shapiro AD, Mahlangu JN, Perry D, Pasi J, Quon DV, Chowdary P, Tsao E, Li S, Innes A, Pierce GF, Allen GA.

Haemophilia. 2017 May;23(3):392-399. doi: 10.1111/hae.13144. Epub 2017 Feb 20.

PMID:
28220631
23.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B.

Thromb Haemost. 2017 Feb 28;117(3):508-518. doi: 10.1160/TH16-05-0398. Epub 2016 Dec 22.

PMID:
28004057
24.

Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, Kerlin BA, Tsao E, Allen G.

Haemophilia. 2017 Jan;23(1):e39-e42. doi: 10.1111/hae.13125. Epub 2016 Dec 11. No abstract available.

PMID:
27943467
25.

Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2016 Nov;17(3):657-660. doi: 10.1016/j.scr.2016.11.010. Epub 2016 Nov 9.

26.

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Kulkarni R, Presley RJ, Lusher JM, Shapiro AD, Gill JC, Manco-Johnson M, Koerper MA, Abshire TC, DiMichele D, Hoots WK, Mathew P, Nugent DJ, Geraghty S, Evatt BL, Soucie JM.

Haemophilia. 2017 Mar;23(2):207-214. doi: 10.1111/hae.13081. Epub 2016 Nov 4.

27.

A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease.

Sood SL, James AH, Ragni MV, Shapiro AD, Witmer C, Vega R, Bolgiano D, Konkle BA.

Haemophilia. 2016 Nov;22(6):e562-e564. doi: 10.1111/hae.13086. Epub 2016 Oct 5. No abstract available.

28.

Variable bleeding phenotype in an Amish pedigree with von Willebrand disease.

Gupta S, Heiman M, Duncan N, Hinckley J, Di Paola J, Shapiro AD.

Am J Hematol. 2016 Oct;91(10):E431-5. doi: 10.1002/ajh.24474. Epub 2016 Aug 22.

29.

A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease.

Duncan NA, Kronenberger WG, Hampton KC, Bloom EM, Rampersad AG, Roberson CP, Shapiro AD.

Patient Prefer Adherence. 2016 Jun 8;10:983-92. doi: 10.2147/PPA.S103874. eCollection 2016.

30.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.

Blood. 2016 May 19;127(20):2481-8. doi: 10.1182/blood-2015-10-673681. Epub 2016 Feb 9.

31.

Multivariate fMRI Approaches to Flexible Sensorimotor Maps in Parietal Cortex.

Barany DA, Shapiro AD, Lee TG.

J Neurosci. 2015 Aug 26;35(34):11763-5. doi: 10.1523/JNEUROSCI.2307-15.2015. No abstract available.

32.

Response to Gringeri et al.: 'Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling'.

Shapiro AD, Li S.

Haemophilia. 2015 Nov;21(6):e489-92. doi: 10.1111/hae.12754. Epub 2015 Jul 14. No abstract available.

PMID:
26173031
33.

Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.

Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.

Haemophilia. 2015 Nov;21(6):791-8. doi: 10.1111/hae.12724. Epub 2015 May 25.

PMID:
26010678
34.

Rare bleeding disorders: diagnosis and treatment.

Palla R, Peyvandi F, Shapiro AD.

Blood. 2015 Mar 26;125(13):2052-61. doi: 10.1182/blood-2014-08-532820. Epub 2015 Feb 23. Review.

PMID:
25712993
35.

Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? Haemophilia Sept 2014;20(5):601-3.

Duncan NA, Roberson CP, Shapiro AD.

Haemophilia. 2015 May;21(3):e235-6. doi: 10.1111/hae.12641. Epub 2015 Feb 16. No abstract available.

PMID:
25684136
36.

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.

37.

Reply: apraxia: a gestural or a cognitive disorder?

Buxbaum LJ, Shapiro AD, Coslett HB.

Brain. 2015 Mar;138(Pt 3):e334. doi: 10.1093/brain/awu240. Epub 2014 Aug 29. No abstract available.

38.

Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications?

Shapiro AD, Akins S, Cooper DL.

Haemophilia. 2014 Sep;20(5):e367-71. doi: 10.1111/hae.12504. Epub 2014 Aug 25. No abstract available.

PMID:
25156940
39.

A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.

Berntorp E, Shapiro AD, Waters J, Astermark J.

Haemophilia. 2014 Sep;20(5):e362-4. doi: 10.1111/hae.12487. Epub 2014 Aug 25. No abstract available.

PMID:
25156443
40.

Critical brain regions for tool-related and imitative actions: a componential analysis.

Buxbaum LJ, Shapiro AD, Coslett HB.

Brain. 2014 Jul;137(Pt 7):1971-85. doi: 10.1093/brain/awu111. Epub 2014 Apr 27.

42.

Long-lasting recombinant factor VIII proteins for hemophilia A.

Shapiro AD.

Hematology Am Soc Hematol Educ Program. 2013;2013:37-43. doi: 10.1182/asheducation-2013.1.37. Review.

PMID:
24319160
43.

The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience.

Heiman M, Gupta S, Shapiro AD.

Haemophilia. 2014 May;20(3):407-12. doi: 10.1111/hae.12313. Epub 2013 Nov 22.

PMID:
24261743
44.

Visual context modulates potentiation of grasp types during semantic object categorization.

Kalénine S, Shapiro AD, Flumini A, Borghi AM, Buxbaum LJ.

Psychon Bull Rev. 2014 Jun;21(3):645-51. doi: 10.3758/s13423-013-0536-7.

45.

Quantitative trait locus linkage analysis in a large Amish pedigree identifies novel candidate loci for erythrocyte traits.

Hinckley JD, Abbott D, Burns TL, Heiman M, Shapiro AD, Wang K, Di Paola J.

Mol Genet Genomic Med. 2013 Sep 1;1(3):131-141.

46.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.

47.

Dissociations of action means and outcome processing in left-hemisphere stroke.

Kalénine S, Shapiro AD, Buxbaum LJ.

Neuropsychologia. 2013 Jun;51(7):1224-33. doi: 10.1016/j.neuropsychologia.2013.03.017. Epub 2013 Apr 6.

48.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2013 May 2;121(18):3742-4. doi: 10.1182/blood-2012-12-471672. Epub 2013 Mar 21.

49.

Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH.

Haemophilia. 2013 Jul;19(4):590-4. doi: 10.1111/hae.12117. Epub 2013 Mar 18.

50.

Radiosynovectomy: review of the literature and report from two haemophilia treatment centers.

Rampersad AG, Shapiro AD, Rodriguez-Merchan EC, Maahs JA, Akins S, Jimenez-Yuste V.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):465-70. doi: 10.1097/MBC.0b013e3283602a28. Review.

PMID:
23492910

Supplemental Content

Loading ...
Support Center